Ifosfamide - History, efficacy, toxicity and encephalopathy

Pharmacol Ther. 2023 Mar:243:108366. doi: 10.1016/j.pharmthera.2023.108366. Epub 2023 Feb 25.

Abstract

In this review we trace the passage of fundamental ideas through 20th century cancer research that began with observations on mustard gas toxicity in World War I. The transmutation of these ideas across scientific and national boundaries, was channeled from chemical carcinogenesis labs in London via Yale and Chicago, then ultimately to the pharmaceutical industry in Bielefeld, Germany. These first efforts to checkmate cancer with chemicals led eventually to the creation of one of the most successful groups of cancer chemotherapeutic drugs, the oxazaphosphorines, first cyclophosphamide (CP) in 1958 and soon thereafter its isomer ifosfamide (IFO). The giant contributions of Professor Sir Alexander Haddow, Dr. Alfred Z. Gilman & Dr. Louis S. Goodman, Dr. George Gomori and Dr. Norbert Brock step by step led to this breakthrough in cancer chemotherapy. A developing understanding of the metabolic disposition of ifosfamide directed efforts to ameliorate its side-effects, in particular, ifosfamide-induced encephalopathy (IIE). This has resulted in several candidates for the encephalopathic metabolite, including 2-chloroacetaldehyde, 2-chloroacetic acid, acrolein, 3-hydroxypropionic acid and S-carboxymethyl-L-cysteine. The pros and cons for each of these, together with other IFO metabolites, are discussed in detail. It is concluded that IFO produces encephalopathy in susceptible patients, but CP does not, by a "perfect storm," involving all of these five metabolites. Methylene blue (MB) administration appears to be generally effective in the prevention and treatment of IIE, in all probability by the inhibition of monoamine oxidase in brain potentiating serotonin levels that modulate the effects of IFO on GABAergic and glutamatergic systems. This review represents the authors' analysis of a large body of published research.

Keywords: 2-Chloroacetaldehyde; 2-Chloroacetic acid; 3-Hydroxypropionic acid; Acrolein; Cyclophosphamide; Encephalopathy; GABA; Glutamate; Ifosfamide; Mitochondria; Nitrogen mustards.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Brain Diseases* / chemically induced
  • Brain Diseases* / drug therapy
  • Cyclophosphamide
  • Humans
  • Ifosfamide / adverse effects
  • Ifosfamide / metabolism
  • Methylene Blue / adverse effects

Substances

  • Ifosfamide
  • Antineoplastic Agents
  • Cyclophosphamide
  • Methylene Blue